Objectives-To study the acute effects of exposure to the increasingly used solvent, N-methyl-2-pyrrolidone (NMP) in male volunteers. Further, to determine the NMP concentration in plasma and urine during and after the exposure.
N-methyl-2-pyrrolidone (NMP; structural formula C5HNO; CAS number 872-50-4; boiling point 202°C at 101-3 kPa) is a widely and increasingly used solvent. The many applications of its commercial uses are due to its strong and selective solvent power. It dissolves most monomers and polymers and catalyses many polymerisation reactions. One of the main uses of NMP is in the petrochemical industry as an extraction agent, and it is also used in the microelectronics fabrication industry, for manufacturing electrolytic capacitors and batteries, as well as in the production of insecticides, herbicides, and fungicides. Furthermore, NMP is used as a penetration enhancer for topically applied drugs. An increasing use of NMP may be as a substitute for other solvents of higher inherent toxicity in occupational and environmental settings-for example, for methylene chloride in paint strippers. The use of NMP as a remover of graffiti has rapidly increased. ' In the rat, NMP is readily absorbed through the skin2 and the respiratory3 and gastrointestinal2 tracts, distributed to all major organs,4 and biotransformed to polar metabolites which are excreted in urine, mainly as 5-hydroxy-Nmethyl-2-pyrrolidone.5 The urinary excretion, studied after application of NMP to the skin, suggests a percutaneous uptake of about 70%.2 Animal studies also show that exposure to NMP may cause degenerative changes in the respiratory system and the haematopoietic and the lymphoid tissues. Effects such as lethargy and irregular respiration found after inhalation and oral administration may be due to a neurotoxic effect. The studies on reproductive toxicity show that NMP may cause developmental toxicity at doses causing mild or no maternal toxicity. 6 The toxicity of NMP in humans is not well known. ' The irritating effect found in the occupational setting on skin and eyes predicts that NMP, in accordance with animal studies,7 may be a moderate to severe irritant. Workers exposed to concentrations of NMP in air ranging from 3-6 mg/m3, for even short periods (30 min), reported severe eye irritation and headache.8 Reversible dermatitis is reported in workers after a few days of work with NMP,9 and experimental skin exposure to NMP in humans caused transient irritation. ' These findings of adverse effects show that exposure to NMP may present a risk of injury to human health. Knowledge of the effect of exposure to NMP in humans is lacking. Human studies involving experimental inhalation are needed for evaluation of the effect of short term exposure. The metabolism in humans needs to be evaluated for assessing the risk of exposure and for studies of the possibility of biological monitoring.
Materials and methods

SUBJECTS AND STUDY DESIGN
Six healthy male volunteers (subjects 1, 2, 3, 4, 5, and 6; age 28, 29, 35, 39, 39, and 41 years; weight 62, 70, 80, 72, 80, and 79 kg; height 170, 183, 178, 176, 186, and 178 cm) were studied. All participants were subject to a general health examination, with special attention to liver, kidney, and haematology. They had no history of nasal problems, no midfacial abnormalities, no notable septal deformities, and no turbinate hypertrophy. They were also examined with allergen skin tests. None of the subjects were using any kind of drug at the time of the experiment, and none had consumed alcohol within the 24 hours before the experiment or as long as urine samples were collected or blood samples were sampled. There were no restrictions on the diet before or after the exposure. During the exposure all subjects at all four exposures had the same diet (after two hours coffee and two slices of bread and cheese; four hours 200 g pizza; six hours coffee and one piece of cake; water as desired). The study was run during February and March, a period when the pollen count in air is low. Two of the subjects responded slightly positively to prick test for histamine (3 mg/ml).
The study design was approved by the ethics committee of Lund University (LU 451-94, Medical Faculty, Lund University, Sweden) , and all six subjects gave their written informed consent to participate in the study.
EXPOSURE
The volunteers were exposed in an exposure chamber (1 5 m x 1-5 m; height 2 5 m) with an air turn over rate of 20 per hour. The subjects were exposed two at a time. There was an exposure free period of about five minutes after two, four, and six hours of exposure for examination and biological sample collection. The concentration of NMP in air was measured by continuously adding NMP on a heated surface (190'C) placed in the air inlet to the chamber. The concentration of NMP in air was levelled by dilution of the NMP with water. The concentration of NMP in air in the chamber was continuously measured with an infrared spectrophotometer (Miran-1A; wavelength um; path length 20-5 m). The exposure was assessed by four consecutive two-hour sampling periods in the personal breathing zone of each subject. The sampling was performed on solid sorbent tubes (Amberlite XAD 7; SKC pumps; 0-2 I/min).
ANALYSIS OF SAMPLES OF NMP IN AIR
The air samples, after collection, were kept in darkness at 4VC and analysed within two days.
The NMP was desorbed from the solid adsorbent (main layer and control layer separately) with 2 ml ethyl acetate with 5% ethanol.10 After shaking for two hours, the organic phase was transferred into glass vials with polyfluorotetraethylene (PFTE) screw caps. The analyses of NMP were performed by gas liquid chromatography (GLC) (Varian 3700; autosampler 8035) with a nitrogen phosphorus detector (NPD; Varian TSD). A 30 m x 0-25 mm internal diameter fused silica column with 0 25 jum DB-5MS (J&W Scientific (Fisons), Folsom, CA, USA) was used. The carrier gas was nitrogen (20 ml/min). The temperature of the split/splitless injector was 220'C, the column 1250C, and the detector 250°C. The peaks were evaluated by integration (Shimadzu C-R3A Chromatopac integrator). Stock NMP solution was dissolved in ethyl acetate with 5% ethanol and stored at 4°C. The calculations of the desorbed concentrations of NMP were made by comparison with diluted stock solutions with added solid adsorbent.
BLOOD ANALYSIS Blood samples were taken, before the start of exposure, immediately after the exposure, and 16 hours after the exposure for the analysis of the number of leucocytes, neutrophils, eosinophils, lymphocytes, basophils, monocytes, and thrombocytes and the concentrations in serum of IgE, bilirubin (conjugated as well as total), alkaline phosphatase (S-ALP), glutamyltransferase (S-GT), aspartate aminotransferase (S-ASAT), and alanine aminotransferase (S-ALAT).
RHINOMETRY
The geometry of the nasal cavity was assessed by continuous acoustic rhinometry (Rhin 2000 with software program 1. 19; SR Electronic, Lynge, Denmark) before and 2, 4, 6, and 8 hours after the start of exposure. At the end of exposure the volunteers were given two puffs of nasal spray (oxymetazolin hydrochloride 0 5 mg/ml) in each nostril (into the inferior and middle nasal meatus) and the decongestion were assessed after 30 minutes. The nasal cavity, both left and right sides, was evaluated by the minimal cross sectional areas found in two distances (d,) between The analyses of NMP were performed by a modification of the same GLC procedure as for samples of NMP in air. The column temperature programming was 1250C for five minutes, 250GC (increasing by 20'C/min), and 250'C for three minutes. Standard samples of NMP in plasma and urine were stored at -16'C and the concentrations of NMP in (right plus left) before and after exposure showed no obvious differences (table 2) . Neither did xylometazolin decongest differently between the experiments. However, the Experimental exposure of male volunteers to N-methyl-2-pyrrolidone (NMP): acute effects and pharmacokinetics ofNMP in plasma and urine Figure 1 Nasal space, as the summed volume (V2; left and right sides) found in the distances between 32 to 64 mm from the nostril, in subject I before, during, and after exposure to 0, 10, 20, and 50 mg/iM3 NMP and after decongestion with two puffs of 0S mg/ml oxymetazolin hydrochloride to each nostril. Figure 1 e curves ing, and on with k during Ls due to ; in the 95% confidence interval (95% CI) w and thus, there may be an undetected in the volume of the nasal cavity. E shows typical nasal cavity volume-tim in one subject (subject 1; before, dun after exposure and after decongestin nasal spray). The decreasing pattern the exposure, typical in all subjects, wa a decreasing activity of the subjects chamber. The high percutaneous uptake of NMP' and the large number of women working with itfor example, in the microelectronics fabrication industry-indicate the urgent need for biological monitoring. However, due to the almost total biotransformation of NMP, the main pathways in humans need to be mapped before a suitable method could be adopted.
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